---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001110"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:06:19.236865+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entera Bio reports FY2024 net loss of $9.5M; cash $21M as of March 28, 2025

## Summary
- Net loss $9.5M ($0.25 per share) vs $8.9M ($0.31 per share) in FY2023.
- Cash and equivalents $8.7M at Dec 31, 2024; $21M as of March 28, 2025 after new investments.
- R&D expenses flat at $4.5M; G&A increased to $5.1M from $4.4M.
- Entera and OPKO entered oral GLP-1/Glucagon license agreement; IND filing expected in 2025.
- EB613 Phase 3 study planned pending FDA surrogate endpoint qualification; SABRE ruling awaited.

## SEC filing metadata
- accession: 0001178913-25-001110
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/0001178913-25-001110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/zk2532935.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001110
- JSON: https://secwatch.observer/filing/0001178913-25-001110.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.